NCM Biopharmaceuticals

Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting
Fierce Biotech
Mon, 10/17/22 - 11:17 pm
NCM Biopharmaceuticals
clinical trials
Merck
age-related macular degeneration